U.S. Reduces Monoclonal Antibody Allocations

The U.S. Office of the Assistant Secretary for Preparedness and Response today confirmed it was distributing 127,236 monoclonal antibody (mAbs) treatments to U.S. states, territories, and agencies this week.

The specific local allocations are listed on this webpage.

This week's allocation is about 98,000 less than the 225,590​ doses distributed during the week of January 17, 2022.

Currently, there are four mAbs Authorized by the U.S. FDA to treat certain patients. However, only two mAbs are being distributed this week:

• Evusheld = 74,976
• Sotrovimab = 52,260

Regarding the effectiveness of these mAbs against SARS-CoV-2 betacoronavirus variants, the U.S. NIH OpenData Portal confirmed on January 24, 2022, positive in vitro therapeutic activity against the Omicron (B.1.1.529) variant. 

The NIH issued an update on January 19, 2022, addressing the fact that the Omicron variant of concern is now the dominant SARS-CoV-2 variant in the Department of Health and Human Services ten regions.

Furthermore, the NIH dashboard indicates Sotrovimab is the most effective mAbs against Omicron.

Vir Biotechnology and GSK's Sotrovimab (Xevudy®) is a pan-sarbecovirus anti-SARS-CoV-2, human neutralizing mAbs selected based on its potential to neutralize the betacoronavirus in vitro, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs.